PRESS RELEASES

Expanding Immunoscore® clinical utility on 3000+ stage III colon cancer patients

HalioDx SAS, the immuno-oncology diagnostic company pioneering the immunological diagnosis of cancers, today announced that Immunoscore® is evaluated in a new study with two cohorts from the prospective randomized IDEA[1] international trial in Stage III Colorectal Cancer[2]: the SCOT[3] cohort in the UK[4]and the HORG[5] cohort in Greece[6].

The objectives of the new Immunoscore® study announced today are to consolidate results obtained in the Immunoscore-IDEA France[7] study for its predictive and prognostic performance in additional independent series. Moreover, the study will investigate Immunoscore® performance in CAPOX treated patients, in order to assist oncologists to select optimal adjuvant chemotherapy regimen for individual patients. The study will be conducted in 3000 patients receiving either FOLFOX or CAPOX chemotherapy.

Updated results from the parent IDEA collaboration showed that Overall Survival and 5 years Disease Free Survival results continue to support the use of 3 months versus 6 months adjuvant chemotherapy for the vast majority of stage III colon cancer patients, but conclusion underlined oncologists’ needs for more accurate risk profiling beyond Tumor/Node stage classification, such as Immune status scoring (i.e. Immunoscore®), to help define the best adjuvant therapy in Stage III colon cancer.

Pr John Souglakos, MD, PhD, University of Heraklion, Crete, commented:This study will provide additional data on the consistency of evaluating immune response at the tumor site to adjust for optimal treatment duration in stage III colon cancer and more specifically data on a CAPOX cohort will be generated. We are very happy to bring a complementary cornerstone of evidence participating in this randomized clinical study in a multicentric framework”.

Vincent FERT, CEO of HalioDx mentioned: ‘We are delighted to work with experts in GI oncology from UK and Greece and access to FOLFOX and CAPOX patients from IDEA study will strengthen Immunoscore® Level of Evidence in stage III colon cancer.” He addedOne of our priority is to provide oncologists with best in class precision medicine tools and this study addresses precisely this objective”.

 


[1] IDEA: International Duration Evaluation of Adjuvant Chemotherapy

[3] SCOT: Short Course Oncology Treatment trial

[5] HORG: Hellenic Oncology Research Group